Tumour infiltrating lymphocyte therapy - Cellular Therapeutics - Obsidian Therapeutics
Alternative Names: Tumour infiltrating lymphocyte (TIL) therapy - Obsidian TherapeuticsLatest Information Update: 28 Sep 2020
At a glance
- Originator Obsidian Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer